AOD-9604 targets lipolysis pathways while CJC-1295 and Ipamorelin support endogenous growth hormone pulse patterns — research suggests this combination is associated with improved body composition markers.

Designed for

Researchers focused on body composition outcomes.

Research cycle structure

Week 1

Week 8

Phase 1

Ramp & establish baseline

Phase 2

Peak protocol window

Phase 3

Taper & recovery

Research Use Only. This compound is sold strictly for in-vitro research and laboratory purposes and is not intended for human consumption or therapeutic use. By purchasing you confirm you are a qualified researcher and agree to our full disclaimer.

Ready to start this protocol?

All 3 compounds, lab CoA included, protocol guide PDF — shipped worldwide.

Not sure? Take the 60-second quiz